# Amprion

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amprion

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: https://ampriondx.com/
- Total disclosed funding: $5.8M
- Latest round: Series B (Sep 10, 2024)
- Investors on record: 2

## About

Based in California, US, and founded in 2007, Amprion, Inc. operates as a biotechnology company that develops precision medicine for neurodegenerative diseases. The company was founded by its CEO, Russ Lebovitz, and CSO, Claudio Soto.

Amprion develops tests to diagnose brain disorders, including Parkinson's and Lewy Body Dementia. The company's product line includes the SYNTap Biomarker Test, which detects misfolded proteins (prions) in the cerebrospinal fluid (CSF) associated with neurodegenerative diseases like Alzheimer's, Parkinson's, and Lewy body dementia. By detecting these misfolded proteins, the SYNTap® test helps doctors diagnose these diseases earlier. The firm uses biomarker testing to develop precision medicine for these diseases.

## Funding rounds

- Series B, Sep 10, 2024, $5.8M — Eli Lilly & Company, Formation Venture Engineering

## Investors

- Eli Lilly & Company — Series B
- Formation Venture Engineering (https://capitalatlas.ai/funds/formation-venture-engineering) — Series B